What's the problem? [Regulatives / Guidelines]

posted by nobody – 2017-05-17 11:31 (2967 d 04:34 ago) – Posting: # 17364
Views: 23,511

PS: No, I don't think that assay performance will do anything to intraindiv. CV of a drug product, as long as

- not practically all samples are around LLOQ
- effects are not random.

Did some sims in the old daysTM, effect of assay when validated according to current recommendations is negligible.

Especially for the "11% CV in 5 other trials, suddenly 40% in my trial" example there is no explanation remotely related to assay.

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
23,425 posts in 4,928 threads, 1,679 registered users;
56 visitors (0 registered, 56 guests [including 10 identified bots]).
Forum time: 16:05 CEST (Europe/Vienna)

Fools with Tools Are Still Fools!    Anonymous

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5